Serina Therapeutics Inc
SER4.330USD
+0.003+0.07%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
43.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Serina Therapeutics Inc Unternehmen
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc Informationen
BörsenkürzelSER
Name des UnternehmensSerina Therapeutics Inc
IPO-datumNov 29, 2018
CEOMr. Steven Ledger
Anzahl der mitarbeiter12
WertpapierartOrdinary Share
GeschäftsjahresendeNov 29
Addresse601 Genome Way,
StadtHUNTSVILLE
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl35806
Telefon12563279630
Websitehttps://serinatherapeutics.com/
BörsenkürzelSER
IPO-datumNov 29, 2018
CEOMr. Steven Ledger
Führungskräfte von Serina Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
130.00K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Oct 2
Aktualisiert: Thu, Oct 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Juvenescence Ltd
31.00%
Puffinus L.P.
8.59%
McMillan (Helen w)
6.72%
The Vanguard Group, Inc.
1.43%
Ledger (Steven A)
0.91%
Andere
51.35%
Aktionäre
Aktionäre
Anteil
Juvenescence Ltd
31.00%
Puffinus L.P.
8.59%
McMillan (Helen w)
6.72%
The Vanguard Group, Inc.
1.43%
Ledger (Steven A)
0.91%
Andere
51.35%
Aktionärstypen
Aktionäre
Anteil
Corporation
39.59%
Individual Investor
8.27%
Investment Advisor
2.66%
Hedge Fund
0.81%
Investment Advisor/Hedge Fund
0.44%
Research Firm
0.03%
Andere
48.19%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
55
415.64K
3.94%
+54.74K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Juvenescence Ltd
3.27M
31%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.59%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.72%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
150.62K
1.43%
+85.29K
+130.55%
Jun 30, 2025
Ledger (Steven A)
95.73K
0.91%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
85.22K
0.81%
--
--
Jun 30, 2025
Waverly Advisors, LLC
67.49K
0.64%
--
--
Jun 30, 2025
Bailey (Gregory Hugh)
67.24K
0.64%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
28.88K
0.27%
-322.00
-1.10%
Jun 30, 2025
Hightower Advisors, LLC
17.91K
0.17%
-3.52K
-16.43%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 18 minutes ago
Aktualisiert: 18 minutes ago
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Datum
Art
Verhältnis
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
